Table 6 Novel agents in clinical trials

CPX-351

(liposomal cytarabine: daunorubicin at 5:1)

Elderly untreated AML

100 u/m² D1,3,5

Phase IIb

45

acceptable toxicity and comparable to standard regimen

[9]

Voreloxin (anticancer quinolone derivative)

Elderly untreated AML

72 mg/m² qw × 3

Phase II

105

CR/CRp: 47%

[45]

Amonafide (AS1413)

Cytarabine

Secondary AML

600 mg/m²/d IV d1-5

Phase II

88

CR/CRi: 42%

[46]

behenoylara-C

Idarubicin

Etoposide

untreated AML

300-350 mg/m²

× 10d

Phase II

165

CR: 87%

[47]

Lenalidomide

Cytarabine, Daunorubicin

5q-AML/MDS

10 mg/d po d1-21

Phase I/II

18

CR/CRi: 47%

[50]

Ribavirin

Cytarabine

AML

13

CR:7%

[51]

ARRY-520

idarubicin

refractory AML

0.8-5.6 mg/m2 IV

Phase I

33

MTD: 4.5 mg/m2

[52]

AZD1152

relapsed AML

50 mg-1600 mg

Phase I/II

64

MTD: 1200 mg

[53]

AZD6244

AML

100 mg po bid

Phase II

47

Feasible treatment

[56]

Terameprocol

relapsed and refractory AML

1000-2200 mg iv, 3/w, ×2-3w

Phase I/II

16

MTD: 1500 mg

[57]